Obe­si­ty drug race heats up as In­novent un­corks new GLP1 da­ta

While Eli Lil­ly has been hy­per-fo­cused on de­thron­ing No­vo Nordisk’s semaglu­tide in the di­a­betes and obe­si­ty space, an­oth­er chal­lenger sneaked up from be­hind.

In­novent Bi­o­log­ics …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER